CHMP nod for GSK's single agent COPD drug Incruse
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has had a second positive opinion on a COPD drug in as many days from the European Medicines Agency's CHMP, which has given its recommendation for the company's Incruse (umeclidinium).